

Cover Story
ClinicalTrials & Tribulations
By Wenora Johnson, Danielle Ripley-Burgess, Heather Hampel, Folasade (Fola) P. May, Anjee Davis and Richard M. Goldberg
Technological advances are transforming our understanding of cancer, accelerating the evolution of new treatment approaches. In the past decades, researchers deploying new techniques for analyzing DNA have extended our knowledge of inherited genetic abnormalities that can predispose a person to develop colorectal and other cancers.
In Brief


Funding Opportunities
Clinical Roundup


Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State
- Breast cancer activists in the 90s got DOD to fund cancer research—now that program has been gutted
- The insinuation that AstroTurf causes GBM has no basis in science
The Philadelphia Inquirer series does disservice to brain tumor community